PMID- 35140612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Understanding the Gut-Kidney Axis in Antineutrophil Cytoplasmic 
      Antibody-Associated Vasculitis: An Analysis of Gut Microbiota Composition.
PG  - 783679
LID - 10.3389/fphar.2022.783679 [doi]
LID - 783679
AB  - Increasing evidence suggested that gut microbiota played critical roles in 
      developing autoimmune diseases. This study investigated the correlation between 
      gut microbiota and antineutrophil cytoplasmic antibody-associated vasculitis 
      (AAV) with kidney injury. We analyzed the fecal samples of 23 AAV patients with 
      kidney injury using a 16s RNA microbial profiling approach. The alpha-diversity 
      indexes were significantly lower in AAV patients with kidney injury than healthy 
      controls (Sobs P < 0.001, Shannon P < 0.001, Chao P < 0.001). The beta-diversity 
      difference demonstrated a significant difference among AAV patients with kidney 
      injury, patients with lupus nephritis (LN), and health controls (ANOSIM, p = 
      0.001). Among these AAV patients, the Deltaproteobacteria, 
      unclassified_o_Bacteroidales, Prevotellaceae, Desulfovibrionaceae Paraprevotella, 
      and Lachnospiraceae_NK4A136_group were correlated negatively with serum 
      creatinine, and the proportion of Deltaproteobacteria, 
      unclassified_o_Bacteroidales, Desulfovibrionaceae, Paraprevotella, and 
      Lachnospiraceae_NK4A136_group had a positive correlation with eGFR. In 
      conclusion, the richness and diversity of gut microbiota were reduced in AAV 
      patients with kidney injury, and the alteration of gut microbiota might be 
      related with the severity of kidney injury of AAV patients. Targeted regulation 
      of gut microbiota disorder might be a potential treatment for AAV patients with 
      kidney injury.
CI  - Copyright (c) 2022 Yu, Li, Ren, Feng, Tao, Cheng, Ma, Gou and Fu.
FAU - Yu, Meilian
AU  - Yu M
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Li, Lingzhi
AU  - Li L
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Ren, Qian
AU  - Ren Q
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Feng, Han
AU  - Feng H
AD  - Department of Biostatistics and Data Science, School of Public Health, University 
      of Texas Health Science Center at Houston, Houston, TX, United States.
FAU - Tao, Sibei
AU  - Tao S
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Cheng, Lu
AU  - Cheng L
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Ma, Liang
AU  - Ma L
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Gou, Shen-Ju
AU  - Gou SJ
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Fu, Ping
AU  - Fu P
AD  - Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan 
      University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20220124
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8819146
OTO - NOTNLM
OT  - ANCA
OT  - gut microbiome
OT  - gut-kidney axis
OT  - kidney disease
OT  - vasculitis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/11 06:00
MHDA- 2022/02/11 06:01
PMCR- 2022/01/24
CRDT- 2022/02/10 05:34
PHST- 2021/09/26 00:00 [received]
PHST- 2022/01/07 00:00 [accepted]
PHST- 2022/02/10 05:34 [entrez]
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/02/11 06:01 [medline]
PHST- 2022/01/24 00:00 [pmc-release]
AID - 783679 [pii]
AID - 10.3389/fphar.2022.783679 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jan 24;13:783679. doi: 10.3389/fphar.2022.783679. 
      eCollection 2022.